Recent studies have reported the protective efficacy of both natural 1 and vaccine-induced
2 , 3 , 4 , 5 , 6 – 7 immunity against challenge with severe acute respiratory syndrome …

The global coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has made the development of a vaccine a top …

The ongoing pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major threat to global health …

A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
may be required to end the coronavirus disease 2019 (COVID-19) pandemic 1 , 2 , 3 , 4 …

Neutralization of Omicron BA.1 and BA.2 Variants Although two doses of BNT162b2 vaccine
produce immunity that wanes over time, the administration of a booster dose substantially …

The highly mutated SARS-CoV-2 Omicron (B.1.1.529) variant has been shown to evade a
substantial fraction of neutralizing antibody responses elicited by current vaccines that encode …

Importance Pregnant women are at increased risk of morbidity and mortality from COVID-19
but have been excluded from the phase 3 COVID-19 vaccine trials. Data on vaccine safety …

An understanding of protective immunity to severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) is critical for vaccine and public health strategies aimed at ending the global …

The Ad26.COV2.S vaccine 1 , 2 – 3 has demonstrated clinical efficacy against symptomatic
COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing …

Kinetics of Immune Response to Covid-19 Vaccines B-cell and T-cell responses were
measured to assess the stability and duration of vaccine-induced immunity. Responses to …